See-Mode Technologies, a MedTech company based in Australia that is on a mission to unlock the hidden insights within medical imaging, today announced that it has received approval from Health Canada for its product expansion to support Breast & Thyroid ultrasound examinations.
See-Mode uses Artificial Intelligence to detect lesions in ultrasound images, then assigns feature classifications to each lesion, in line with the American College of Radiology’s BI-RADS and TI-RADS rating systems. Sonographer worksheets, complete with lesion classifications and diagrams are instantly generated and sent to PACS, while preliminary impressions are sent to radiology reporting systems. In follow-up scans, See-Mode allows for fast comparison between old and new images, and will automatically highlight changes in lesion characteristics.
“Receiving approval from Health Canada is a significant step forward for us at See-Mode, which demonstrates the applicability of our software beyond the vascular studies we currently support”, said Dr. Milad Mohammadzadeh, Co-Founder and Director, See-Mode Technologies. “Working closely with clinicians we learned that the reporting of Breast & Thyroid examinations was notoriously time-consuming, subjective, and error-prone, especially when there are multiple lesions present. We are excited to enable clinicians across Canada to complete their reports more efficiently and provide a second set of eyes on the study making sure nothing is missed.”
“See-Mode represents a tremendous step forward by combining the power of Artificial Intelligence with the expertise of a clinical sonographer and radiologist. See-Mode eliminates tedious manual steps in the interpretation and reporting of ultrasound images, improves efficiency, and provides unparalleled consistency of reporting between different members of the radiology team. This is a system that truly understands the content of ultrasound images.” Martin Necas, Specialist Sonographer, Waikato Hospital, Clinical Consultant for See-Mode.
